Disease · MONDO_0005012
cutaneous melanoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cutaneous melanoma. Diseases, record MONDO_0005012. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005012
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cutaneous (skin) melanoma, cutaneous melanoma (disease), malignant cutaneous melanoma, malignant ear melanoma, malignant lip melanoma, malignant lower limb melanoma, malignant melanoma (of skin), stage unspecified, malignant melanoma of ear and/or external auricular canal, malignant melanoma of skin, malignant melanoma of skin of lower limb, malignant melanoma of skin of trunk except scrotum, malignant melanoma of skin of upper limb, malignant neck melanoma, malignant scalp melanoma, malignant trunk melanoma, malignant upper limb melanoma, melanoma (disease) of zone of skin, melanoma of skin, melanoma of the skin, skin melanoma, zone of skin melanoma, zone of skin melanoma (disease)
- Open Targets
Drugs81
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LIFILEUCEL | CHEMBL4298200 | Cell | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| DABRAFENIB | CHEMBL2028663 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| TRAMETINIB | CHEMBL2103875 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| INTERFERON ALFA-2B | CHEMBL1201558 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DACARBAZINE | CHEMBL476 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TALIMOGENE LAHERPAREPVEC | CHEMBL2108727 | Gene | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 81
See all 81 drugsTargets84
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 6 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist | Phase 3 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist | Phase 3 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 4 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Phase 3 | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 4 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Phase 3 | https://conductscience.org/library/genes/5605 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 3 | Serine/threonine-protein kinase B-raf inhibitor | Phase 3 | https://conductscience.org/library/genes/673 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 1/2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 2 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
1 to 10 of 84
See all 84 targetsTrials75
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | Phase 3 | 765 | 2023-04-21 | Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin) | BEMPEGALDESLEUKIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma | Phase 3 | 704 | 2014-12-04 | Melanoma | DABRAFENIB, TRAMETINIB, VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT01584648 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | Phase 3 | 423 | 2014-08-15 | Melanoma | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01693068 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | Phase 2 | 194 | 2018-01-05 | N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma | DACARBAZINE, PIMASERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT01320085 | A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | Phase 2 | 183 | 2021-01-05 | BRAF or NRAS Mutant Metastatic Melanoma | BINIMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Phase 1/2 | 161 | 2025-12-10 | Advanced or Metastatic Solid Tumors | PEMBROLIZUMAB, SUBASUMSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02083354 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | Phase 2 | 77 | 2021-03-17 | Cancer, Melanoma | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | Phase 2 | 48 | 2017-03-30 | Melanoma | DACARBAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Phase 1/2 | 45 | 2024-12-27 | Neoplasms, Melanoma | MODAKAFUSP ALFA, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | Phase 1/2 | 39 | 2017-07-02 | Metastatic Melanoma | DECITABINE, PANOBINOSTAT, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 75
See all 75 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Combination of Bempegaldesleukin (NKTR-214) + Nivolumab vs Nivolumab: deaths from any cause | 9 of 378 | 4 of 387 | 765 | NCT04410445 | Trial comparisons |
| Combination of Bempegaldesleukin (NKTR-214) + Nivolumab vs Nivolumab: serious adverse events | 74 of 378 | 33 of 387 | 765 | NCT04410445 | Trial comparisons |
| Dabrafenib + Trametinib vs Dabrafenib + Placebo: Objective Response Rate (ORR) as Assessed by the Investigator | 146 of 210 | 113 of 210 | 420 | NCT01584648 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: Number of Patients With Dose Limiting Toxicities (DLT). | 2 of 16 | 0 of 7 | 23 | NCT00145158 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: deaths from any cause | 0 of 16 | 0 of 7 | 23 | NCT00145158 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: serious adverse events | 7 of 16 | 3 of 7 | 23 | NCT00145158 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: deaths from any cause | 0 of 14 | 0 of 8 | 22 | NCT02288897 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: Number of Participants With Adverse Events | 14 of 14 | 8 of 8 | 22 | NCT02288897 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: serious adverse events | 0 of 14 | 1 of 8 | 22 | NCT02288897 | Trial comparisons |
Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg vs Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg: Phase 2 Expansion: Number of Participants With Grade 3 or Higher TEAEs | 6 of 9 | 7 of 12 | 21 | NCT04157517 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005012
GET https://conductscience.org/api/diseases/v1/MONDO_0005012/drugs?page=2